Comment on “Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials”

The study "Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials" evaluates inclisiran's efficacy and safety in reducing LDL cholesterol levels across diverse patient populations. Twelve clinical trials were reviewed, demonstrating consis...

Full description

Saved in:
Bibliographic Details
Published in:Current problems in cardiology 2024-06, Vol.49 (6), p.102516, Article 102516
Main Authors: Rangwala, Hussain Sohail, Fatima, Hareer, Riaz, Faiza, Rangwala, Burhanuddin Sohail
Format: Article
Language:English
Subjects:
Cholesterol, LDL - blood
Clinical Trials as Topic
Dyslipidemias - drug therapy
Dyslipidemias - genetics
Dyslipidemias - therapy
Humans
RNA, Small Interfering - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study "Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials" evaluates inclisiran's efficacy and safety in reducing LDL cholesterol levels across diverse patient populations. Twelve clinical trials were reviewed, demonstrating consistent LDL-C reduction, even in statin intolerance or resistance cases, with sustained efficacy observed over various durations, some extending up to four years. Inclisiran exhibited a favorable safety profile, suggesting its potential as a well-tolerated treatment option. Despite promising findings, the limitations include the short duration of some trials and the exclusion of non-English language studies, warranting further research. Future studies should focus on the long-term safety and efficacy in diverse patient populations and explore the broader clinical implications of inclisiran. Although inclisiran shows promise in dyslipidemia management, comprehensive research is needed to understand its full potential in cardiovascular medicine.
ISSN:0146-2806
1535-6280
1535-6280
DOI:10.1016/j.cpcardiol.2024.102516